Browse studies

Find your next paid study

322 recruiting studies matching your filters

Blinded Reference Set for Multicancer Early Detection Blood Tests

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing …

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAnn Arbor Stage I Lymphoma+59 more

Estimated

~$10 – $750

Alliance for Clinical Trials in OncologyNCT05334069

Phase 1

Phase 1 Study With Dose Expansion of the Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

Background: Mesothelioma is an aggressive cancer that grows in the linings of the body; this can include the membranes that line the heart, lungs, and interna…

MesotheliomaNeoplasmsStomach Neoplasms+5 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06885697

Phase 1

Individualized Response Assessment to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Primaries

Background: Cytoreductive surgery (CRS) removes tumors in the abdomen. HIPEC is hyperthermic (heated) chemotherapy that washes the inside of the abdomen. CRS …

Peritoneal MesotheliomaPeritoneal CarcinomatosisOvarian Cancer+4 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT04847063

Phase 1

A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors

The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid…

Metastatic Solid TumorRecurrent Solid TumorAdvanced Solid Tumor+11 more

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT06465069

Observational

Distance-Based Exercise to Preserve Function and Prevent Disability

This clinical trial studies whether an exercise program can be successfully delivered to patients receiving treatment for cancer through virtual sessions and a…

Localized Malignant Solid NeoplasmAnal CancerBladder (Urothelial, Transitional Cell) Cancer+16 more

Estimated

~$10 – $6,250

Alliance for Clinical Trials in OncologyNCT07059884

Biorepository in Participants Who Undergo OTC for Gonadotoxic Therapy

Background: Medical advances have improved survival rates for many cancers and other illnesses. This means that more people are coping with the long-term effe…

Acute Ovarian FailureInfertilityEarly Menopause And Infertility In Females After Treatment For Childhood Cancer

Estimated

~$10 – $675

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NCT05440617

Phase 1

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with…

Advanced Solid TumorAdvanced Malignant NeoplasmMetastatic Cancer+27 more

Estimated

~$10 – $8,750

Phase 1

A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN003694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer

This phase Ib trial tests the safety, side effects, and best dose of M1774 when given with ZEN-3694 in treating patients with ovarian and endometrial cancer th…

Recurrent Endometrial CarcinomaRecurrent Endometrial Clear Cell AdenocarcinomaRecurrent Endometrial Endometrioid Adenocarcinoma+6 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT05950464

Phase 2

MC1963 Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for Patients With Advanced Stage Ovarian Cancer: A Phase II Double-Blind Randomized Clinical Trial (FAROUT)

This phase II trial compares the effect of folate receptor alpha dendritic cells (FRαDCs) to placebo in treating patients with stage III or IV ovarian, fallopi…

Advanced Fallopian Tube CarcinomaAdvanced Fallopian Tube High Grade Serous AdenocarcinomaAdvanced Ovarian Carcinoma+15 more

Estimated

~$10 – $6,250

DICER1-Related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study

Background: \- Pleuropulmonary blastoma (PPB) is a rare fast-growing lung tumor that is associated with other, rare tumor types. Most cases of PPB appear in c…

Pleuropulmonary BlastomaCystic NephromaOvarian Sertoli-Leydig Cell Tumors+2 more

Estimated

~$10 – $675

National Cancer Institute (NCI)NCT01247597

Phase 3

A Randomised, Open-label, Phase III Study of Torvutatug Samrotecan in Combination With Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Treatment in Participants With Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (TREVI-OC-02)

This study will evaluate the efficacy, safety and tolerability of Torvutatug samrotecan (torvu-sam) in combination with bevacizumab compared with bevacizumab m…

Epithelial Ovarian Cancer

Estimated

~$10 – $7,500

AstraZenecaNCT07851025

Phase 1

A Phase 1/2a Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

This is a Phase 1/2a dose escalation and expansion study to determine the safety, tolerability, and preliminary clinical activity of 177LuBetaBart, a lutetium-…

Castration-Resistant Prostate Cancer (CRPC)Colorectal CancerNSCLC (Non-small Cell Lung Cancer)+8 more

Estimated

~$10 – $8,750

Radiopharm Theranostics, LtdNCT07189871